VIR-7831 represent a emerging class of immunoglobulin therapies designed to neutralize the SARS-CoV-2 agent. Initially , sotrovimab, created by Vir Biotechnology , demonstrated considerable benefit https://owainwszs054937.blognody.com/51268790/sotrovimab-vir-7831-a-deep-exploration-into-the-immunoglobulin-therapy